2024
ARID1A in Gynecologic Precancers and Cancers
Morgan J, Jaferi N, Shonibare Z, Huang G. ARID1A in Gynecologic Precancers and Cancers. Reproductive Sciences 2024, 31: 2150-2162. PMID: 38740655, DOI: 10.1007/s43032-024-01585-w.Peer-Reviewed Original ResearchARID1A alterationsGynecologic cancerTumor suppressor ARID1AResponse to chemotherapeutic agentsFrequency of genetic alterationsLoss-of-function mutationsSWI/SNF complex subunitsFemale reproductive tractFunction of ARID1ARadiation therapyTumor-suppressive actionAtypical hyperplasiaARID1A mutationsARID1A deficiencyTherapeutic vulnerabilitiesChemotherapeutic agentsGenetic alterationsImmune modulationClinical evidenceARID1ASignaling pathway interactionsSuppressive actionEndoplasmic reticulumProtein expressionCancer
2023
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.Peer-Reviewed Original ResearchConceptsHyperthermic intraperitoneal chemotherapyIntraperitoneal chemotherapyOvarian cancerStage III epithelial ovarian cancerUse of HIPECEpithelial ovarian cancerHigh-quality evidenceOvarian cancer treatmentHIPEC useInterval cytoreductionCytoreductive surgeryNeoadjuvant chemotherapyPerioperative careHIPEC protocolsHIPEC techniqueTreatment modalitiesPatient outcomesSingle administrationTumor disseminationChemotherapyCancerCancer treatmentOptimal candidatesMain siteLife data
2022
Intersections of endocrine pathways and the epithelial mesenchymal transition in endometrial cancer
Gelissen JH, Huang GS. Intersections of endocrine pathways and the epithelial mesenchymal transition in endometrial cancer. Frontiers In Oncology 2022, 12: 914405. PMID: 36052252, PMCID: PMC9424890, DOI: 10.3389/fonc.2022.914405.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsEpithelial-mesenchymal transitionEndometrial cancerMesenchymal transitionRegulation of EMTTherapeutic interventionsInvasive capacityCancer metastasisEpithelial originEndocrine pathwaysMesenchymal phenotypeCancerCancer cellsEndocrine signalingMetastasisSignaling pathwaysCritical regulatorMortalityPathwayPotential avenuesRandomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2022, 126: 1695-1703. PMID: 35149854, PMCID: PMC8853032, DOI: 10.1038/s41416-022-01717-6.Peer-Reviewed Original ResearchConceptsPrimary peritoneal cancerPeritoneal cancerPredictive biomarkersDay 1Taxane-resistant ovarian cancerPhase II trialM2 days 1Bevacizumab 10Evaluable patientsPrior bevacizumabWeekly ixabepiloneII trialPrimary endpointSecondary endpointsRefractory statusTUBB3 expressionPrior receiptSubgroup analysisClinical trialsOvarian cancerIxabepilonePFSCancerBevacizumabPatients
2019
Stratifying Ovarian Cancer Risk Using Personal Health Data
Hart GR, Nartowt BJ, Muhammad W, Liang Y, Huang GS, Deng J. Stratifying Ovarian Cancer Risk Using Personal Health Data. Frontiers In Big Data 2019, 2: 24. PMID: 33693347, PMCID: PMC7931902, DOI: 10.3389/fdata.2019.00024.Peer-Reviewed Original ResearchOvarian cancer riskCancer riskOvarian Cancer Screening TrialNational Health Interview SurveyCancer Screening TrialHigh-risk populationHealth Interview SurveyHealth dataOvarian cancer detectionDifferent risk categoriesPublic health organizationsOvarian cancerScreening TrialGeneral populationLower riskPersonal health dataTargeted screeningGenetic testingRisk categoriesHealth OrganizationInterview SurveyCancerCharacteristic curveNon-invasive wayCancer detection
2018
Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, Van Le L, Ghamande S, González-Santiago S, Bover I, Graña Suárez B, Green A, Huot-Marchand P, Bourhis Y, Karve S, Blakeley C. Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer. Journal Of Clinical Oncology 2018, 36: 1300-1307. PMID: 29558274, PMCID: PMC6804908, DOI: 10.1200/jco.2017.76.2781.Peer-Reviewed Original ResearchConceptsOvarian cancerTesting pathwayFaster treatment decisionsManagement of patientsGenetic counselorsBRCA mutation testingMedian turnaround timeOvarian Cancer StudyOncologist satisfactionOncology teamAnalysis populationPatient satisfactionTest counselingPretest counselingTreatment decisionsBRCA testingTurnaround timePatientsMutation testingBRCAmCancerENGAGE studyTesting guidelinesWeeksCancer studies
2017
Genetic landscape of clear cell endometrial cancer and the era of precision medicine
Huang GS, Santin AD. Genetic landscape of clear cell endometrial cancer and the era of precision medicine. Cancer 2017, 123: 3216-3218. PMID: 28485840, PMCID: PMC5907932, DOI: 10.1002/cncr.30743.Commentaries, Editorials and Letters
2015
IGF2 signaling and regulation in cancer
Brouwer-Visser J, Huang GS. IGF2 signaling and regulation in cancer. Cytokine & Growth Factor Reviews 2015, 26: 371-377. PMID: 25704323, DOI: 10.1016/j.cytogfr.2015.01.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2007
Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors
Huang GS, Gebb JS, Einstein MH, Shahabi S, Novetsky AP, Goldberg GL. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. American Journal Of Obstetrics And Gynecology 2007, 196: 243.e1-243.e5. PMID: 17346538, DOI: 10.1016/j.ajog.2006.09.035.Peer-Reviewed Original ResearchConceptsHigh-grade endometrial tumorsPreoperative endometrial samplingEndometrial samplingEndometrial tumorsEndometrial cancer patientsHigh-grade cancerLow-grade cancerNonendometrioid histologyPathologic reviewHysterectomy specimensSingle institutionCancer patientsHistologic diagnosisTumor gradePipelleCurettageTumorsPatientsDiagnosisKappa statisticsCancerHistology
2005
Consolidation therapy for ovarian cancer
Huang G, Goldberg G, Fields A. Consolidation therapy for ovarian cancer. The Women's Oncology Review 2005, 5: 3-8. DOI: 10.3109/14733400500070708.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsWhole abdominal radiotherapyConsolidation therapyOvarian cancerCatheter-related complicationsRecurrence-free intervalLate radiation toxicityConsolidation regimensPaclitaxel therapyOverall survivalSurvival benefitBiologic agentsRandomized studyCA 125Randomized trialsRadiation toxicityMEDLINE searchTherapyCancerToxic agentsClinical acceptanceRadiotherapyInternational meetingsRegimensChemotherapyComplications